B6-hGIPR Mouse
製品名
B6-hGIPR Mouse
製品ID
C001858
系統名
C57BL/6NCya-Giprem1(hGIPR)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「B6-hGIPR Mouse（カタログ番号C001858）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
PGQTL2
NCBI ID
染色体
Chr 19
MGI ID
さらに
系統詳細
The GIPR gene encodes the gastric inhibitory polypeptide receptor (GIPR), a G protein-coupled receptor with notable expression in pancreatic β-cells, and also detected in the gastrointestinal tract, adipose tissue, and brain [1-2]. The GIPR protein acts as the cognate receptor for gastric inhibitory polypeptide (GIP), a key incretin hormone that potentiates glucose-dependent insulin secretion, thereby regulating systemic glucose homeostasis [2]. While prominently expressed in pancreatic β-cells, GIPR is also present in tissues including the stomach and small intestine [3]. Dysregulation of GIPR function and genetic variants within GIPR have been implicated in metabolic disorders such as type 2 diabetes and obesity, and potentially in the pathogenesis of endocrine tumors and retinoblastoma [4-5]. Emerging evidence suggests a role for GIPR signaling in immunomodulation and inflammation within the gut, highlighting its potential relevance in inflammatory bowel diseases [3]. Currently, therapeutic monoclonal antibodies targeting GIPR are being explored for the treatment of diabetes and obesity. Intriguingly, GIPR may exhibit context-dependent roles within tumor microenvironments, with some evidence suggesting tumor-suppressive functions in specific cancers such as retinoblastoma [4-5]. This multifaceted nature positions GIPR as a compelling therapeutic target for metabolic and inflammatory diseases and potentially selected malignancies.
B6-hGIPR mouse is a humanized model generated using gene editing technology, in which the Exon 3~14 of the coding sequence (CDS) encoding the human GIPR protein and the 3'UTR of mouse Gipr gene are integrated into a specific site within the mouse Gipr gene, while retaining the endogenous gene sequence encoding the murine signal peptide (aa.1~18) and aa.19. This model can be used for studying the pathological mechanisms and therapeutic approaches of metabolic and inflammatory diseases and potentially selected malignancies, as well as for the development of GIPR-targeted drugs.
参考文献
Liskiewicz A, Müller TD. Regulation of energy metabolism through central GIPR signaling. Peptides. 2024 Jun;176:171198.
Samms RJ, Sloop KW, Gribble FM, Reimann F, Adriaenssens AE. GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders. Diabetes. 2021 Sep;70(9):1938-1944.
Morrow NM, Morissette A, Mulvihill EE. Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut. Peptides. 2024 Jun;176:171200.
Haase A, Alefeld E, Yalinci F, Meenen DV, Busch MA, Dünker N. Gastric Inhibitory Polypeptide Receptor (GIPR) Overexpression Reduces the Tumorigenic Potential of Retinoblastoma Cells. Cancers. 2024; 16(9):1656.
Jonathan E. Campbell, Jacqueline L. Beaudry, Berit Svendsen, Laurie L. Baggio, Andrew N. Gordon, John R. Ussher, Chi Kin Wong, Fiona M. Gribble, David A. D’Alessio, Frank Reimann, Daniel J. Drucker; GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue. Diabetes 1 May 2022; 71 (5): 1115–1127.
系統作製戦略
The exon 3 to partial intron 3 of mouse Gipr was replaced with Exon 3~14 of Human GIPR CDS-3'UTR of Mouse Gipr-WPRE-BGH pA cassette. The murine signal peptide and aa.19 were preserved.
Figure 1. Gene editing strategy of B6-hGIPR mice.
適用分野
GIPR-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of metabolic and inflammatory diseases and potentially selected malignancies.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。